Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Stock Price Target Lowered at Truist Financial

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) had its price target cut by analysts at Truist Financial from $25.00 to $24.00 in a research report issued on Monday, Benzinga reports. The brokerage presently has a “hold” rating on the stock. Truist Financial’s target price suggests a potential upside of 13.13% from the stock’s previous close.

Several other analysts have also recently commented on the stock. Zacks Research raised shares of Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. Weiss Ratings upgraded Fresenius Medical Care AG & Co. KGaA from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday. BNP Paribas Exane downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating and set a $19.90 price objective for the company. in a research report on Tuesday, July 28th. Citigroup reissued a “neutral” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Friday, July 17th. Finally, Berenberg Bank set a $24.00 price target on Fresenius Medical Care AG & Co. KGaA in a report on Tuesday, September 29th. Eight analysts have rated the stock with a Hold rating and five have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Reduce” and an average target price of $23.42.

Fresenius Medical Care AG & Co. KGaA Stock Performance

FMS stock traded up $0.15 during trading on Monday, hitting $21.21. The company had a trading volume of 503,225 shares, compared to its average volume of 709,553. Fresenius Medical Care AG & Co. KGaA has a 1-year low of $20.02 and a 1-year high of $27.54. The company has a quick ratio of 0.75, a current ratio of 1.07 and a debt-to-equity ratio of 0.43. The firm has a 50-day moving average price of $22.92 and a 200-day moving average price of $22.91. The firm has a market cap of $11.40 billion, a PE ratio of 10.99, a price-to-earnings-growth ratio of 3.85 and a beta of 0.74.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last announced its quarterly earnings data on Monday, August 3rd. The company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.62 by $0.04. The firm had revenue of $5.55 billion during the quarter, compared to the consensus estimate of $5.48 billion. Fresenius Medical Care AG & Co. KGaA had a net margin of 4.83% and a return on equity of 9.28%. On average, analysts expect that Fresenius Medical Care AG & Co. KGaA will post 2.28 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Farther Finance Advisors LLC boosted its stake in Fresenius Medical Care AG & Co. KGaA by 39.1% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,915 shares of the company’s stock valued at $43,000 after buying an additional 538 shares in the last quarter. QRG Capital Management Inc. increased its position in Fresenius Medical Care AG & Co. KGaA by 15.7% in the 2nd quarter. QRG Capital Management Inc. now owns 89,267 shares of the company’s stock valued at $2,018,000 after acquiring an additional 12,139 shares in the last quarter. Sequoia Financial Advisors LLC increased its position in Fresenius Medical Care AG & Co. KGaA by 95.0% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 39,527 shares of the company’s stock valued at $894,000 after acquiring an additional 19,252 shares in the last quarter. Tidal Investments LLC raised its stake in shares of Fresenius Medical Care AG & Co. KGaA by 96.0% in the second quarter. Tidal Investments LLC now owns 99,790 shares of the company’s stock worth $2,256,000 after acquiring an additional 48,885 shares during the last quarter. Finally, Integrated Wealth Concepts LLC bought a new position in shares of Fresenius Medical Care AG & Co. KGaA in the second quarter worth about $91,000. Institutional investors and hedge funds own 8.37% of the company’s stock.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is a Germany-based health care company focused on the treatment of chronic kidney disease and kidney failure. The company provides dialysis care through a global network of outpatient clinics and supports patients with related medical services, including vascular access care, laboratory services and care coordination.

In addition to operating dialysis facilities, Fresenius Medical Care develops and manufactures products used in dialysis treatment.